Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis

Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, Sugimachi K: Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg. 1995, 180 (5): 577-582.

Rüdiger Siewert J, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1, 002 consecutive patients. Ann Surg. 2000, 232 (3): 353-361. 10.1097/00000658-200009000-00007

Nakane Y, Okamura S, Boku T, Okusa T, Tanaka K, Hioki K: Prognostic differences of adenocarcinoma arising from the cardia and the upper third of the stomach. Am Surg. 1993, 59 (7): 423-429.

Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-729. 10.1056/NEJMoa010187

Feng AN, Zhang LH, Fan XS, Huang Q, Ye Q, Wu HY, Yang J: Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int J Surg Pathol. 2011, 19 (6): 743-750. 10.1177/1066896911412181

Pinto-de-Sousa J, David L, Almeida R, Leitão D, Preto JR, Seixas M, Pimenta A: c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol. 2002, 10 (4): 247-256. 10.1177/106689690201000402

Liu M, Li JS, Tian DP, Huang B, Rosqvist S, Su M: MCM2 expression levels predict diagnosis and prognosis in gastric cardiac cancer. Histol Histopathol. 2013, 28 (4): 481-492.

Shi R, Wang L, Wang T, Xu J, Wang F, Xu M: NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma. Med Oncol. 2014, 31 (3): 852-

Zhang Q, Wang H, Ma Y, Zhang J, He X, Ma J, Zhao ZS: Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol. 2014, 31 (7): 33-

Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, Wu ZJ, Cheng GJ, Wang F, Ni F, Wang XL, Cao GX, Huang J, Cai J: NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol. 2014, 35 (7): 6351-6356. 10.1007/s13277-014-1839-7

Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006, 24 (30): 4922-4927. 10.1200/JCO.2006.07.1316

Staub O, Gautschi I, Ishikawa T, Breitschopf K, Ciechanover A, Schild L, Rotin D: Regulation of stability and function of the epithelial Na + channel (ENaC) by ubiquitination. EMBO J. 1997, 16 (21): 6325-6336. 10.1093/emboj/16.21.6325

Staub O, Dho S, Henry P, Correa J, Ishikawa T, McGlade J, Rotin D: WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na + channel deleted in Liddle's syndrome. EMBO J. 1996, 15 (10): 2371-2380.

Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z, Fladd C, Parkinson J, Rotin D: Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol. 2009, 5: 333-350.

Magnifico A, Ettenberg S, Yang C, Mariano J, Tiwari S, Fang S, Lipkowitz S, Weissman AM: WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem. 2003, 278: 43169-43177. 10.1074/jbc.M308009200

Woelk T, Oldrini B, Maspero E, Confalonieri S, Cavallaro E, Di Fiore PP, Polo S: Molecular mechanisms of coupled monoubiquitination. Nat Cell Biol. 2006, 8: 1246-12454. 10.1038/ncb1484

Blot V, Perugi F, Gay B, Prévost MC, Briant L, Tangy F, Abriel H, Staub O, Dokhélar MC, Pique C: Nedd4.1-mediated ubiquitination and subsequent recruitment of Tsg101 ensure HTLV-1 Gag trafficking towards the multivesicular body pathway prior to virus budding. J Cell Sci. 2004, 117 (Pt 11): 2357-2367.

Katz M, Shtiegman K, Tal-Or P, Yakir L, Mosesson Y, Harari D, Machluf Y, Asao H, Jovin T, Sugamura K, Yarden Y: Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic. 2002, 3 (10): 740-751. 10.1034/j.1600-0854.2002.31006.x

Aoh QL, Castle AM, Hubbard CH, Katsumata O, Castle JD: SCAMP3 negatively regulates epidermal growth factor receptor degradation and promotes receptor recycling. Mol Biol Cell. 2009, 20 (6): 1816-1832. 10.1091/mbc.E08-09-0894

Lin Q, Wang J, Childress C, Sudol M, Carey DJ, Yang W: HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates EGF-induced degradation of EGFR and ACK. Mol Cell Biol. 2010, 30: 1541-1554. 10.1128/MCB.00013-10

Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007, 128: 129-139. 10.1016/j.cell.2006.11.039

Amodio N, Scrima M, Palaia L, Salman AN, Quintiero A, Franco R, Botti G, Pirozzi P, Rocco G, De Rosa N, Viglietto G: Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol. 2010, 177 (5): 2622-2634. 10.2353/ajpath.2010.091075

Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, Jeong SY, Hwang JJ, Lee SJ, Suh YA, Kim I, Nam KY, Han S, Kim JE, Kim KP, Hong YS, Lee JL, Lee WJ, Choi EK, Lee JS, Jin DH, Kim TW: p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ. 2014, 21 (1): 146-160. 10.1038/cdd.2013.141

Jung S, Li C, Jeong D, Lee S, Ohk J, Park M, Han S, Duan J, Kim C, Yang Y, Kim KI, Lim JS, Kang YS, Lee MS: Oncogenic function of p34SEI-1 via NEDD4–1–mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int J Oncol. 2013, 43 (5): 1587-1595.

Yang Z, Yuan XG, Chen J, Lu NH: Is NEDD4-1 a negative regulator of phosphatase and tensin homolog in gastric carcinogenesis?. World J Gastroenterol. 2012, 18 (43): 6345-6348. 10.3748/wjg.v18.i43.6345

Kim SS, Yoo NJ, Jeong EG, Kim MS, Lee SH: Expression of NEDD4-1, a PTEN regulator, in gastric and colorectal carcinomas. APMIS. 2008, 116 (9): 779-784. 10.1111/j.1600-0463.2008.00999.x

Fouladkou F, Landry T, Kawabe H, Neeb A, Lu C, Brose N, Stambolic V, Rotin D: The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A. 2008, 105 (25): 8585-8590. 10.1073/pnas.0803233105

Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, Chen J: WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol. 2011, 13 (6): 728-733.

Eide PW, Cekaite L, Danielsen SA, Eilertsen IA, Kjenseth A, Fykerud TA, Ågesen TH, Bruun J, Rivedal E, Lothe RA, Leithe E: NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cell Signal. 2013, 25 (1): 12-18. 10.1016/j.cellsig.2012.08.012

Salah Z, Cohen S, Itzhaki E, Aqeilan RI: NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation. Cell Cycle. 2013, 12 (24): 3817-3823. 10.4161/cc.26672

Park JG, Frucht H, LaRocca RV, Bliss DP, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson BE, Bang Y-J, Kim J-P, Gazdar AF: Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 1990, 50: 2773-2780.

Barranco SC, Townsend CM, Casartelli C, Macik BG, Burger NL, Boerwinkle WR, Gourley WK: Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res. 1983, 43 (4): 1703-1709.

Lin HL, Chiou SH, Wu CW, Lin WB, Chen LH, Yang YP, Tsai ML, Uen YH, Liou JP, Chi CW: Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells. J Pharmacol Exp Ther. 2007, 323 (1): 365-373. 10.1124/jpet.107.124966

Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P: Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res. 2008, 68 (11): 4277-4286. 10.1158/0008-5472.CAN-07-6517

Shen Z, Kauttu T, Seppänen H, Vainionpää S, Ye Y, Wang S, Mustonen H, Puolakkainen P: Both macrophages and hypoxia play critical role in regulating invasion of gastric cancer in vitro. Acta Oncol. 2013, 52 (4): 852-860. 10.3109/0284186X.2012.718444

Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, Pavletich NP, Carver BS, Cordon-Cardo C, Erdjument-Bromage H, Tempst P, Chi SG, Kim HJ, Misteli T, Jiang X, Pandolfi PP: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007, 128 (1): 141-156. 10.1016/j.cell.2006.11.040

Arteaga C: Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003, 30 (3 Suppl 7): 3-14.

Tysnes BB, Haugland HK, Bjerkvig R: Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Invasion Metastasis. 1997, 17 (5): 270-280.

Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P, Giannopoulou I: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res. 2008, 10 (3): R49- 10.1186/bcr2103

Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J. 2002, 16 (13): 1823-1825.

Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Möller G, Junker R, Assmann G, Zaenker KS: c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J. 1999, 13 (14): 1939-1949.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004, 350 (21): 2129-2139. 10.1056/NEJMoa040938

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304 (5676): 1497-1500. 10.1126/science.1099314

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004, 101 (36): 13306-13311. 10.1073/pnas.0405220101